Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human Interleukin 33 Antibodies:
anti-Mouse (Murine) Interleukin 33 Antibodies:
anti-Rat (Rattus) Interleukin 33 Antibodies:
Go to our pre-filtered search.
Mouse (Murine) Polyclonal Interleukin 33 Primary Antibody for CyTOF, ELISA (Capture) - ABIN4899216
Denney, Byrne, Shea, Buckley, Pease, Herledan, Walker, Gregory, Lloyd: Pulmonary Epithelial Cell-Derived Cytokine TGF-β1 Is a Critical Cofactor for Enhanced Innate Lymphoid Cell Function. in Immunity 2015
Show all 43 Pubmed References
Mouse (Murine) Monoclonal Interleukin 33 Primary Antibody for CyTOF, FACS - ABIN4899217
Hudson, Christophi, Gruber, Wilmore, Lawrence, Massa: Induction of IL-33 expression and activity in central nervous system glia. in Journal of leukocyte biology 2008
Show all 15 Pubmed References
Mouse (Murine) Monoclonal Interleukin 33 Primary Antibody for FACS - ABIN4895750
Kempuraj, Thangavel, Yang, Pattani, Zaheer, Santillan, Santillan, Zaheer: Dopaminergic Toxin 1-Methyl-4-Phenylpyridinium, Proteins α-Synuclein and Glia Maturation Factor Activate Mast Cells and Release Inflammatory Mediators. in PLoS ONE 2015
Show all 8 Pubmed References
Mouse (Murine) Polyclonal Interleukin 33 Primary Antibody for ELISA (Detection), FACS - ABIN4899215
Kim, Morita, Kobayashi, Eisenbarth, Lee, Elias, Eynon, Flavell: AMCase is a crucial regulator of type 2 immune responses to inhaled house dust mites. in Proceedings of the National Academy of Sciences of the United States of America 2015
Show all 8 Pubmed References
Human Monoclonal Interleukin 33 Primary Antibody for Func, IP - ABIN1169172
Pace, Di Sano, Sciarrino, Scafidi, Ferraro, Chiappara, Siena, Gangemi, Vitulo, Giarratano, Gjomarkaj: Cigarette smoke alters IL-33 expression and release in airway epithelial cells. in Biochimica et biophysica acta 2014
Show all 4 Pubmed References
Human Polyclonal Interleukin 33 Primary Antibody for ELISA, WB - ABIN1002522
Dinarello: Interleukin-18, a proinflammatory cytokine. in European cytokine network 2000
Show all 4 Pubmed References
Human Polyclonal Interleukin 33 Primary Antibody for FM, ELISA - ABIN1002523
Chackerian, Oldham, Murphy, Schmitz, Pflanz, Kastelein: IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. in Journal of immunology (Baltimore, Md. : 1950) 2007
Show all 4 Pubmed References
Human Polyclonal Interleukin 33 Primary Antibody for WB - ABIN541618
Brint, Xu, Liu, Dunne, McKenzie, ONeill, Liew: ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. in Nature immunology 2004
Show all 3 Pubmed References
Human Monoclonal Interleukin 33 Primary Antibody for ELISA, ICC - ABIN4325184
Katwa, Wang, Urankar, Podila, Hilderbrand, Fick, Rao, Ke, Wingard, Brown: A carbon nanotube toxicity paradigm driven by mast cells and the IL-₃₃/ST₂ axis. in Small (Weinheim an der Bergstrasse, Germany) 2012
Show all 3 Pubmed References
The level of stromal interleukin-33 (IL-33) was significantly upregulated in advanced versus early stage head and neck squamous cell carcinoma (HNSCC) patients.
The data implicate TSLP and IL-33 in the pathogenesis of asthma that is characterized by persistent airway inflammation and impaired lung function despite intensive corticosteroid therapy, highlighting them as potential molecular targets.
Data show that expression of IL-33 is increased within epithelial cells of intestinal tumors in humans and mice; promotes tumor development when overexpressed in intestinal cells of ApcMin/+ mice; and its signaling deletion by deletion of ST2, significantly reduces tumorigenesis in these animals. IL-33 overexpression promoted the expansion of ST2+ regulatory T cells and induction of a Th2 cytokine milieu in the colon.
IL-33 might delay dental stem cell pool exhaustion caused by activation stimuli, triggered by inflammation or stress, which initiate their functional response.
Contrary to previous studies demonstrating an antitumor effort in pancreatic cancer, the results of the present study indicated that IL33 exhibited a significant oncopromoting effect on ovarian cancer.
Interleukin-33/ST2 pathway is expressed in the failing human heart and its expression is associated with cardiac fibrosis and pro-fibrotic signaling proteins, suggesting a role in pro-fibrotic myocardial remodeling.
these findings provide evidence that IL-33 induced secretion of IL-31 from LAD2 mast cells
High serum soluble IL-33 receptor predicted exacerbation within the general asthmatic population.
serum IL-33 level was significantly elevated in patients with various types of parotid gland tumors and its sST2 receptor levels were significantly higher in pleomorphic adenoma and acinic cell carcinoma patients compared to the controls.
Low levels of IL-33 and increased levels of sST2 predict mortality risk in critically ill patients independent from each other and APACHE II score. Both together showed additive predictive value suggesting a pathogenic role of the IL-33/ST2 system in critically ill patients.
DAMP molecular IL-33 augmented the 'storm' of monocytic inflammation in response to LPS through ERK1/2 activation during hepatitis B-precipitated acute-on-chronic liver failure.
Both depression exacerbation and posttraumatic stress disorder co-morbidity led to elevated levels of IL-33 and (iNOS, HO-1 and MIP-1beta).
This study demonstrates that the presence of rs928413(G) allele in the IL33 promoter results in its increased activity in a human lung carcinoma cell line due to binding of the cAMP (cyclic adenosine monophosphate) response element binding protein 1 (CREB1) transcription factor. The results offer a tentative explanation for the negative effect of rs928413 on asthma development.
IL-33 has a role in the pathogenesis of autoimmune hepatitis (AIH) and affects the expression of IL-4, IL-17A, and of hypergammaglobulinemia
The serum levels of IL-33 and IL-31 were significantly up-regulated in both AR and allergic asthma patients compared with normal individuals.
chromatin binding is a post-translational mechanism that regulates the releasability and ST2-mediated bioactivity of IL-33.
Results indicate that the interaction between FLIL33 and IPO5 is localized to a specific segment of the FLIL33 protein, is not required for nuclear localization of FLIL33, and protects FLIL33 from proteasome-dependent degradation.
Data suggest that targeting interleukin 33 (IL-33) may be an effective treatment for sepsis-induced immunosuppression.
Oxidative stress is involved in the expression of IL-33 in airway epithelial cells via MAPK signal pathway and IL-33 expression is augmented during viral infection.
IL-33 expression plays an important role in patients with chronic rhinosinusitis with nasal polyp.
IL-33 plays a disease-exacerbating role in experimental dengue infection, probably driven by CXCR2-expressing cells, leading to elevated pro-inflammatory response-mediated pathology.
The results suggest that IL-33 is a potential tissue-specific factor controlling Regulatory T-Cell homeostasis via increased Regulatory T-Cell proliferation in the liver.
the homeostatic release of IL33 by dying colon epithelial cells in the absence of preexisting chronic or acute inflammation protects against the initiation and development of sporadic colon cancer.
results collectively suggest that the IL-33/ST2 axis mediates the activation of innate immune responses and contributes to urothelial hyperplasia by regulating urothelial differentiation in obstructive kidney injury.
Innate immunity-driven type 2 immune responses of the ocular surface are dependent on IL-33, TSLP, basophils, and ILC2. These components may be possible therapeutic targets for refractory allergic keratoconjunctivitis.
Nod1(+/+) mice with chronic H. pylori infection exhibited significantly increased gastric IL-33 and splenic IL-13 responses, but decreased IFN-gamma responses, when compared with Nod1(-/-) animals. Collectively, our data identify NOD1 as an important regulator of mucosal IL-33 responses in H. pylori infection. We suggest that NOD1 may play a role in protection against excessive inflammation.
data provide clear evidence that IL-33 plays a protective role in dextran sulfate sodium-induced chronic colitis
IL-33 promotes the egress of ILC2Ps from the bone marrow. Mice lacking IL-33 signaling had a significant accumulation of ILC2Ps in the bone marrow, including during the critical perinatal period associated with ILC2 accumulation in tissues.
Il33 -/- mice exhibited reduced anxiety-like behaviors in the elevated plus maze and the open field test, as well as deficits in social novelty recognition, despite their intact sociability, in the three-chamber social interaction test. The immunoreactivity of c-Fos proteins, an indicator of neuronal activity, was altered in several brain regions implicated in anxiety-related behaviors.
this paper shows that IL-33 promotes gastrointestinal allergy in a TSLP-independent manner
our findings demonstrate the critical roles of interleukin 33 in promoting colorectal cancer development through inducing tumor-infiltrating ST2L+ regulatory T cells
Combined blockade of the IL-13 and IL-33 pathways leads to a greater inhibition of type 2 inflammation over inhibition of either pathway alone.
Taken together, our data provide the evidence that ST2 deficiency in early phase of sepsis downregulates myeloid precursors, inflammatory NK and dendritic cells
data indicate that during acute, resolving colitis, IL-33/ST2 plays a crucial role in gut mucosal healing by inducing epithelial-derived miR-320 that promotes epithelial repair/restitution and the resolution of inflammation.
IL-33 may down-regulate CLDN1 expression through the ERK/STAT3 pathway in keratinocytes.
the release of IL-33 and GM-CSF from epithelial cells induces the activation of p65 and the p38-MK2/3 signaling module in Dendritic Cells, resulting in Th2 polarization and, finally, allergic inflammation.
Injection of IL-21-expressing or IL-33-expressing plasmids facilitates clearance of pre-established genotype B strain designated BPS (BPS) persistence and protects cured mice from BPS re-challenge.
In a model of sepsis, IL-33 treatment enhanced the IFN-gamma level in blood and promoted mice's survival, so the protective effects of IL-33 depend on IFN-gamma. The IL-33 treatment also promoted both gammadelta T cells and NK cells in septic mice.
VHL-HIF-glycolysis axis is essential for the late-stage maturation and function of ILC2s via targeting IL-33-ST2 pathway.
IL-33 may be a key molecule operating in eosinophil-mediated fibrosis in high-dose-per fraction irradiated skin.
IL33 (MIM 608678) is a member of the IL1 (see MIM 147760) family that potently drives production of T helper-2 (Th2)-associated cytokines (e.g., IL4\; MIM 147780). IL33 is a ligand for IL33R (IL1RL1\; MIM 601203), an IL1 family receptor that is selectively expressed on Th2 cells and mast cells (summary by Yagami et al., 2010
, DVS27-related protein
, interleukin-1 family member 11
, nuclear factor for high endothelial venules
, nuclear factor from high endothelial venules